VALN
Valneva SE - ADR

2,093
Mkt Cap
$840.65M
Volume
8,229.00
52W High
$12.25
52W Low
$4.56
PE Ratio
-7.13
VALN Fundamentals
Price
$9.77
Prev Close
$10.07
Open
$9.62
50D MA
$8.98
Beta
0.93
Avg. Volume
23,987.64
EPS (Annual)
-$0.1818
P/B
4.74
Rev/Employee
$257,267.93
Loading...
Loading...
News
all
press releases
Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume - Still a Buy?
Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Here's Why...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Valneva (NASDAQ:VALN) Shares Gap Up - What's Next?
Valneva (NASDAQ:VALN) Shares Gap Up - Time to Buy...
MarketBeat·14d ago
News Placeholder
Valneva (NASDAQ:VALN) Shares Up 4.9% - What's Next?
Valneva (NASDAQ:VALN) Trading Up 4.9% - What's Next...
MarketBeat·20d ago
News Placeholder
Valneva (NASDAQ:VALN) Stock Price Down 4.6% - Time to Sell?
Valneva (NASDAQ:VALN) Shares Down 4.6% - Here's Why...
MarketBeat·21d ago
News Placeholder
Valneva (NASDAQ:VALN) Shares Gap Up - Time to Buy?
Valneva (NASDAQ:VALN) Shares Gap Up - Still a Buy...
MarketBeat·22d ago
News Placeholder
Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors
Goldman's Small-Cap Biotech Universe: The 2026 Catalyst Playbook For Investors There are just nine days left in the year, and this year has flown by. We've delivered readers a steady stream of 2026...
Zero Hedge·28d ago
News Placeholder
Valneva (NASDAQ:VALN) Downgraded by Wall Street Zen to Sell
Wall Street Zen cut shares of Valneva from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
Valneva (NASDAQ:VALN) Stock Price Down 3.1% - What's Next?
Valneva (NASDAQ:VALN) Shares Down 3.1% - Here's What Happened...
MarketBeat·2mo ago
News Placeholder
Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Here's What Happened
Valneva (NASDAQ:VALN) Sees Strong Trading Volume - What's Next...
MarketBeat·2mo ago
News Placeholder
Valneva's Lyme Vaccine VLA15 Shows Strong Phase 2 Booster Results With Favorable Safety
(RTTNews) - Valneva SE (VALN) announced positive final immunogenicity and safety data from its Phase 2 study, VLA15-221, evaluating the Lyme disease vaccine candidate VLA15. The study results...
Nasdaq News: Markets·2mo ago
<
1
2
...
>

Latest VALN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.